EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Final data from the German AHEAD study: effectiveness and safety of octocog alfa and rurioctocog alfa pegol for hemophilia A in a real-world setting

Robert Klamroth, Karin Kurnik iD, Swee Wenning, Carmen Escuriola-Ettingshausen iD, Stephan Regensburger iD, Leilei Tang, Joan Gu, Randy Guerra, Johannes Oldenburg

Therapeutic Advances in Hematology · 2026-05 · 17

DOI: 10.1177/20406207261419337 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Hematology, online erschienen am 03.05.2026. Verfasst von Robert Klamroth und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin, Ger…. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Takeda Pharma Vertrieb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Octocog alfa and rurioctocog alfa pegol have demonstrated efficacy in the prevention and management of bleeding associated with hemophilia A (HA) in clinical trials. The German AHEAD study (DRKS00000556) was designed to provide real-world data over a long period to complement these studies.

Objectives

To assess real-world long-term outcomes in patients with moderate/severe HA receiving octocog alfa or rurioctocog alfa pegol in routine clinical practice Design: Noninterventional, prospective, study conducted between 2010 and 2022.

Methods

The primary endpoint was the incidence of hemophilia-affected joint arthropathy. Secondary endpoints included annualized bleeding rate and joint bleeding rate (ABR/AJBR), and octocog alfa and rurioctocog alfa pegol consumption. Final data are presented.

Results

The analysis included 377 patients aged 1–80 years who received octocog alfa (severe HA, n = 309; moderate HA, n = 68) and 99 patients aged ⩾12 years who received rurioctocog alfa pegol (severe, n = 82; moderate, n = 17). Over 8 years of follow-up, average Gilbert scores were maintained with prophylaxis. In patients with severe HA, median ABRs/AJBRs were generally lower with prophylaxis versus on-demand treatment, whereas in moderate HA, bleeding rates were similar. Treatment-related adverse events (AEs) and serious treatment-related AEs were reported in 5.3% and 4.2% (35 events including hemorrhage, arthropathy, and factor FVIII (FVIII) inhibitor development) of patients receiving octocog alfa, respectively, and 5.1% and 4.0% of patients receiving rurioctocog alfa pegol, respectively. One previously treated patient receiving octocog alfa developed de novo FVIII inhibitors.

Conclusion

These real-world data corroborate previous clinical trial and real-world data demonstrating the long-term effectiveness and safety of octocog alfa and rurioctocog alfa pegol in patients with HA. In patients with severe HA, octocog alfa prophylaxis was associated with reduced bleeding rates compared with on-demand therapy.

Trial registration

Deutsches Register Klinischer Studien (German Clinical Trials Register): DRKS00000556.

Schlagwörter

Stichwörter der Autor:innen

hemophilia Aoctocog alfaprophylaxisreal-world clinical trialrurioctocog alfa pegol

Autor:innen und Institutionen

  • Department for Internal Medicine, Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Landsberger Allee 49, 10249 Berlin, Germany.
  • Institute for Experimental Hematology and Transfusion Medicine, Bonn University Clinic, Bonn, Germany.
  • Department of Pediatrics, Pediatric Haemophilia Center, Dr. von Hauner Children's Hospital, LMU University Hospital Munich, Munich, Germany.
  • SRH Kurpfalzkrankenhaus, Heidelberg, Germany.
  • Hämophilie-Zentrum Rhein Main GmbH, Frankfurt/Main, Germany.
  • Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany.

ORCID-Profile: Karin Kurnik, Carmen Escuriola-Ettingshausen, Stephan Regensburger

Förderung

  • Takeda Pharma Vertrieb

Zitieren

APA

Klamroth, R., Kurnik, K., Wenning, S., Escuriola-Ettingshausen, C., Regensburger, S., Tang, L., Gu, J., Guerra, R., & Oldenburg, J. (2026). Final data from the German AHEAD study: effectiveness and safety of octocog alfa and rurioctocog alfa pegol for hemophilia A in a real-world setting. Therapeutic Advances in Hematology, 17. https://doi.org/10.1177/20406207261419337

Vancouver

Klamroth R, Kurnik K, Wenning S, Escuriola-Ettingshausen C, Regensburger S, Tang L, et al. Final data from the German AHEAD study: effectiveness and safety of octocog alfa and rurioctocog alfa pegol for hemophilia A in a real-world setting. Therapeutic Advances in Hematology. 2026;17. doi:10.1177/20406207261419337

BibTeX
@article{Klamroth2026,
  author = {Klamroth, Robert and Kurnik, Karin and Wenning, Swee and Escuriola-Ettingshausen, Carmen and Regensburger, Stephan and Tang, Leilei and Gu, Joan and Guerra, Randy and Oldenburg, Johannes},
  title = {Final data from the German AHEAD study: effectiveness and safety of octocog alfa and rurioctocog alfa pegol for hemophilia A in a real-world setting},
  journal = {Therapeutic Advances in Hematology},
  year = {2026},
  volume = {17},
  doi = {10.1177/20406207261419337}
}
Kostenlos starten →